Interferon Alpha and hTERT mRNA in Chronic Hepatitis B Patients
Author Information
Author(s): Zhu Chuan-wu, Chen Ming, Luo Xiang-rong, Wang Hai-yan, Wang Li-hua, Wu Jian-hong, Li Ming, Zhang Xue-hua, Zhu Wei, Ye Jian-zhong, Qian Feng
Primary Institution: The Fifth People's Hospital of Suzhou
Hypothesis
Does IFNα therapy affect hTERT mRNA expression in PBMCs of patients with chronic hepatitis B?
Conclusion
IFNα therapy significantly increases hTERT mRNA expression in PBMCs of chronic hepatitis B patients.
Supporting Evidence
- Mean NhTERT mRNA level was lower in CHB patients but increased significantly in the IFNα-treated group.
- Patients with longer duration of IFNα treatment had higher levels of NhTERT mRNA.
- NhTERT mRNA was significantly correlated with CD3+ T lymphocyte count and CD4+/CD8+ ratio.
Takeaway
This study found that a treatment called IFNα can help increase a specific marker in blood cells that is important for keeping the immune system healthy in people with chronic hepatitis B.
Methodology
The study involved measuring hTERT mRNA levels in PBMCs from chronic hepatitis B patients before and after IFNα treatment.
Potential Biases
Potential biases may arise from the selection of study subjects and the lack of randomization.
Limitations
The study did not directly analyze hTERT mRNA levels among subjects due to variability in PBMC counts and RNA concentration.
Participant Demographics
The study included 37 patients in the IFNα-treated group, 36 in the CHB control group, and 10 healthy controls, with a median age of 27.3 years.
Statistical Information
P-Value
p=0.015 for HBeAg loss subgroup comparison
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website